Zoledronic acid (Zometa®) use in bone disease

Expert Review of Anticancer Therapy

Volumn 3, Issue 2, 2003, Pages 157-165

  Theriault, Richard L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bisphosphonate; Bone metastases; Osteoclast inhibition; Osteoporosis; Paget's disease of bone

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DEOXYPYRIDINOLINE; PACLITAXEL; PAMIDRONIC ACID; PEPTIDE DERIVATIVE; PLACEBO; ZOLEDRONIC ACID;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE DENSITY; BONE DISEASE; BONE METABOLISM; BONE METASTASIS; BONE MINERAL; BONE PAIN; BREAST CANCER; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DUAL ENERGY X RAY ABSORPTIOMETRY; FATIGUE; FEVER; HUMAN; LUNG CANCER; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUTROPENIA; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; REVIEW; SOLID TUMOR;

EID: 0037394329     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.3.2.157     Document Type: Review

References (78)

1. Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: results of comparative preclinical studies. Sem. Oncol. 48, 4-10 (2001).
2. Fleisch H, Russell RGG, Bisaz S, Casey PA, Muhlbauer RC. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution of calcium phosphate in vitro and in vivo. Calcif. Tissue Res. 2(Suppl.), 10-10a (1968).
3. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science 165, 1262 (1969).
4. Fleisch H, Russell RGG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212, 901-903 (1966).
5. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif. Tissue Int. 38, 342-349 (1986).
6. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 18, 75-85 (1996).
7. Compston JE. Bone marrow and bone: a functional unit. J. Endocrinol. 173, 387-396 (2002).
8. Roodman GD. Biology of osteoclast activation in cancer. J. Clin. Oncol. 19, 3562-3571 (2001).
9. Roodman GR. Cell biology of the osteoclast. Exp. Hematol. 27, 1229-1241 (1999).
10. Guise TA. Molecular mechanisms of osteolytic bone metastases. Cancer 88, 2892-2898 (2000).
11. Kanis JA, McCloskey EV. Bone turnover and biochemical markers in malignancy. Cancer 80, 1538-1545 (1997).
12. Reddy SV, Kurihara N, Menaa C, Roodman GD. Paget's disease of bone: a disease of the osteoclast. Rev. Endocr. Metab. Disord. 2, 195-201 (2001).
13. Roodman GD. Studies in Paget's disease and their relevance to oncology. Sem. Oncol. 28, 15-21 (2001).
14. Neale SD, Smith R, Wass JA, Athanasou NA. Osteoclast differentiation from circulating mononuclear precursors in Paget's disease is hypersensitive to 1,25-dihydroxyvitamin D(3) and RANKL. Bone 27, 409-416 (2000).
15. Menaa C, Reddy SV, Kurihara N et al. Enhanced RANK ligand expression and responsivity of bone marrow cells in Paget's disease of bone. J. Clin. Invest. 105, 1833-1838 (2000).
16. Manolagas SC. Role of cytokines in bone resorption. Bone 17, 63S-67S (1995).
17. Manolagas SC. The role of IL-6 type cytokines and their receptors in bone. Ann. NY Acad. Sci. 840, 194-204 (1998).
18. Shevde NK, Bendixen AC, Dienger KM, Pike JW. Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression. Proc. Natl Acad. Sci. USA 97, 7829-7834 (2000).
19. Guise TA. Parathyroid hormone-related protein and bone metastases. Cancer 80, 1572-1580 (1997).
20. Mundy GR. Mechanisms of bone metastasis. Cancer 80, 1546-1556 (1997).
21. Widler L, Jaeggi KA, Glatt M et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J. Med. Chem. 45, 3721-3738 (2002).
22. Rogers MJ, Gordon S, Benford HL et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 88, 2961-2978 (2000).
23. Murakami H, Takahashi N, Sasaki T et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone 17, 137-144 (1995).
24. Selander K, Lehenkari P, Vaananen HK. The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif. Tissue Int. 55(5), 368-375 (1994).
25. Gordon S, Helfrich MH, Sati HI et al. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma. Br. J. Hematol. 119, 475-483 (2002).
26. Dunford JE, Thompson K, Coxon FP et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther. 296, 235-242 (2001).
27. Lerner EC, Hamilton AD, Sebti SM. Inhibition of Ras prenylation: a signaling target for novel anticancer drug design. Anticancer Drug Des. 12, 229-238 (1997).
28. Tamanoi F, Kato-Stankiewicz J, Jiang C, Machado I, Thapar N. Farnesylated proteins and cell cycle progression. J. Cell. Biochem. 37(Suppl.), 64-70 (2001).
29. Jagdev SP, Coleman RE, Shipman CM, Rostami H, Croucher PI. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br. J. Cancer 84, 1126-1134 (2001).
30. Benford HL, McGowan NW, Helfrich MH, Nuttall ME, Rogers MJ. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone 28, 465-473 (2001).
31. Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J. Bone Miner. Res. 15, 2211-2221 (2000).
32. Viereck V, Emons G, Lauck V et al. Bisphosphonates, pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem. Biophys. Res. Commun. 291, 680-686 (2002).
33. Wood J, Bonjean K, Ruetz S et al. Novel anti-angiogenic effects of the bisphosphonate compound zoledronic acid. J. Pharmacol. Exp. Ther. 302, 1055-1061 (2002).
34. Green JR, Muller K, Jaeggi KA. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J. Bone Miner. Res. 9, 745-751 (1994).
35. Risser F, Pfister CU, Degen PH. An enzyme inhibition assay for the quantitative determination of the new bisphosphonate zoledronate in plasma. J. Pharm. Biomed. Anal. 15, 1877-1880 (1997).
36. Evans CE, Braidman IP. Effects of two novel bisphosphonates on bone cells in vitro. Bone. Miner. 26, 95-107 (1994).
37. Reinholz GG, Getz B, Pederson L et al. Bisphosphonates directly regulate cell proliferation, differentiation and gene expression in human osteoblasts. Cancer Res. 60, 6001-6007 (2000).
38. Pataki A, Muller K, Green JR, Ma YF, Li QN, Jee WSS. Effects of short-term treatment with bisphosphonates zoledronate and pamidronate on rate bone: a comparative histomorphometric study on the cancellous bone formed before, during and after treatment. Anat. Rec. 249, 458-468 (1997).
39. Muehleman C, Green J, Williams JM, Kuettner KE, Thonar EJ, Sumner DR. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage 10, 226-233 (2002).
40. Podworny NV, Kandel RA, Renlund RC, Grynpas MD. Partial chondroprotective effect of zoledronate in a rabbit model of inflammatory arthritis. J. Rheum. 26, 1972-1982 (1999).
41. Pysklywec MW, Moran EL, Bogoch ER. Zoledronate (CGP 42'446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis. J. Orthop. Res. 15, 858-861 (1997).
42. Muller K, Wiesenberg I, Jaeggi K, Green JR. Effects of the bisphosphonate zoledronate on bone loss in the ovariectomized and in the adjuvant arthritic rat. Arzneimittelforchung 48, 81-86 (1998).
43. Binkley N, Kimmel D, Bruner J et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J. Bone Miner. Res. 13, 1775-1782 (1998).
44. Green JR. Antitumor potential of bisphosphonates. Med. Klin. 95, 23-28 (2000).
45. Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 61, 2602-2608 (2001).
46. Senaratne SG, Pirianov G, Minsi JL, Arnett TR, Colston KW. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br. J. Cancer 82, 1459-1468 (2000).
47. Boissier S, Magnetto S, Frappart L et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. Cancer Res. 57, 3890-3894 (1997).
48. Boissier S, Ferreras M, Peyruchaud O et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 60, 2949-2954 (2000).
49. Gassone P, Forciniti S, Galea E et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia 14, 841-844 (2000).
50. Derenne S, Amiot M, Barille S et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J. Bone Miner. Res. 14, 2048-2056 (1999).
51. Heikkila P, Teronen O, Moilanen M et al. Bisphosphonates inhibit stromelysin-1 (MMP-3), matrix metalloelastase (MMP-12), collagenase-3 (MMP-13) and enamelysin (MMP-20) but not urokinase-type plasminogen activator and diminish invasion and migration of human malignant and endothelial cell lines. Anticancer Drugs 13, 245-254 (2002).
52. Adami S, Mian M, Gatti P et al. Effects of two oral doses of alendronate in the treatment of Paget's disease of bone. Bone 15, 415-417 (1994).
53. Adami S, Salvagno G, Guarrera G et al. Treatment of Paget's disease of bone with iv. 4-amino-1-hydroxybutylidene-1,1-bisphosphonate. Calcif. Tissue Int. 39, 226-229 (1986).
54. Lyles KW, Siris ES, Singer FR, Meunier PJ. A clinical approach to diagnosis and management of Paget's disease of bone. J. Bone Miner. Res. 16, 1379-1387 (2001).
55. Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases Type II collagen breakdown in patients with Paget's disease of bone. Bone 28, 461-464 (2001).
56. Buckler H, Fraser W, Hosking D et al. Single infusion of zoledronate in Paget's disease of bone: a placebo-controlled, dose-ranging study. Bone 24, 81S-85S (1999).
57. Reid IR, Brown JP, Burckhardt P et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N. Engl. J. Med. 346, 653-661 (2002).
58. Solomon CG. Bisphosphonates and osteoporosis. N. Engl. J. Med. 346, 2 (2002).
59. Body JJ, Lortholary A, Romieu G, Vigneron AM, Ford J. A dose-finding study of zoledronate in hypercalcemic cancer patients. J. Bone Miner. Res. 14, 1557-1561 (1999).
60. Major P, Lortholary A, Hon J et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J. Clin. Oncol. 19, 558-567 (2001).
61. Hortobagyi GN, Theriault RL, Porter L et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lyric bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N. Engl. J. Med. 335, 1785-1791 (1996).
62. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J. Clin. Oncol. 17, 846-854 (1999).
63. Lipton A, Theriault RL, Hortobagyi GN et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long-term follow-up of two randomized, placebo-controlled trials. Cancer 88, 1082-1090 (2000).
64. Berenson JR, Rosen LS, Howell A et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91, 1191-1200 (2001).
65. Berenson JR, Bescio RA, Rosen LS et al. A Phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin. Cancer Res. 7, 478-485 (2001).
66. Rosen LS, Gordon D, Antonio BS et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a Phase III, double-blind, comparative trial. Cancer 7, 377-387 (2001).
67. Rosen L, Gordon D, Dugan W et al. Zoledronic acid (4 mg) is more effective than pamidronate (90 mg) for treating bone metastases in breast cancer patients with at least one osteolytic lesion. Eur. Soc. Med. Oncol. Congress. 18, 22 (2002).
68. Berruti A, Osella G, Raucci CA et al. Transient increase in total serum alkaline phosphatase predicts radiological response to systemic therapy in breast cancer patients with osteolytic and mixed bone metastases. Oncology (Huntingt) 50, 218 (1993).
69. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br. J. Cancer 82, 858-864 (2000).
70. Carlin BI, Andriole GL. The natural history, skeletal complications and management of bone metastases in patients with prostate carcinoma. Cancer 88, 2989-2994 (2000).
71. Townsend MF, Sanders WH, Northway RO, Graham SD. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer 79, 545-550 (1997).
72. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J. Natl. Cancer Inst. 94, 1458-1468 (2002).
73. Rosen L, Gordon D, Tchekmedyian V et al. Zoledronic acid (Zol) significantly reduces skeletal-related evens (SREs) in patients with bone metastases from solid tumors. Proc. Am. Soc. Clin. Oncol. 21, 295a (2002).
74. Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol. Toxicol. 80, 225-230 (1997).
75. Ali SM, Esteva FJ, Hortobagyi G et al. A. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J. Clin. Oncol. 19, 3434-3437 (2001).
76. DesHarnais CL, Bajwa Y, Markle JP, Timbie JW, Zacker C, Schulman KA. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support. Care Cancer 7, 545-551 (2001).
77. McCloskey EV, Guest JF, Kanis JA. The clinical and cost considerations of bisphosphonates in preventing bone complications in patients with metastatic breast cancer or multiple myeloma. Drugs 61, 1253-1274 (2001).
78. Hillner BE. Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease. Semin. Oncol. 4, 64-68 (2001).